City

Montreal (1)

Paris (1)

Condition

Conjunctivitis, Vernal (2)

Conjunctivitis, Allergic (1)

Overall Status

Completed (1)

Recruiting (1)

Sign in for free

Phase

phase 2/phase 3 (1)

phase 4 (1)

Sponsor

Michael Marchand, MD (1)

Santen SAS (1)

Collaborator

Universite de Montreal (1)

Intervention

cyclosporine nova22007 0.05% (1)

cyclosporine nova22007 0.1% (1)

hyaluronic acid 0.05% & ectoine 2.0% (1)

olopatadine hydrochloride ophthalmic solution 0.1% (1)

vehicle (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

conjunctivitis, vernal

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Conjunctivitis, Vernal Trial in Paris (Cyclosporine NOVA22007 0.05%, Cyclosporine NOVA22007 0.1%, Vehicle)

Completed

Has Results

Conjunctivitis, Vernal

Cyclosporine NOVA22007 0.05%
+2 more

Paris, France

Groupe Hospitalier Bichat-Claude Bernard

Nov 12, 2021

Conjunctivitis, Allergic, Conjunctivitis, Vernal Trial in Montréal (Hyaluronic acid 0.05% & Ectoine 2.0%, Olopatadine HCl

Recruiting

Conjunctivitis, Allergic
Conjunctivitis, Vernal

Hyaluronic acid 0.05% & Ectoine 2.0%
Olopatadine hydrochloride ophthalmic solution 0.1%

Montréal, Quebec, Canada

CHU Sainte-Justine Hospital

Oct 20, 2020